Clinical Trials Directory

Trials / Completed

CompletedNCT06775834

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Safety and Pharmacokinetic Study of HRS-1893 Tablets in Subjects With Mild and Moderate Renal Insufficiency and Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Shandong Suncadia Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.

Conditions

Interventions

TypeNameDescription
DRUGHRS-1893HRS-1893 tablets.

Timeline

Start date
2025-02-11
Primary completion
2025-07-23
Completion
2025-07-23
First posted
2025-01-15
Last updated
2025-09-10

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06775834. Inclusion in this directory is not an endorsement.